SonoScape Medical Future Growth

Future criteria checks 3/6

SonoScape Medical is forecast to grow earnings and revenue by 54% and 13.5% per annum respectively. EPS is expected to grow by 53.1% per annum. Return on equity is forecast to be 15.4% in 3 years.

Key information

54.0%

Earnings growth rate

53.1%

EPS growth rate

Medical Equipment earnings growth	25.5%
Revenue growth rate	13.5%
Future return on equity	15.4%
Analyst coverage	Good
Last updated	10 Jan 2025

Recent future growth updates

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Oct 28

Recent updates

Is SonoScape Medical (SZSE:300633) Using Too Much Debt?

Jan 06

Is There An Opportunity With SonoScape Medical Corp.'s (SZSE:300633) 23% Undervaluation?

Dec 22

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Oct 28

Investors Appear Satisfied With SonoScape Medical Corp.'s (SZSE:300633) Prospects As Shares Rocket 28%

Oct 21

These 4 Measures Indicate That SonoScape Medical (SZSE:300633) Is Using Debt Reasonably Well

Sep 20

Weak Statutory Earnings May Not Tell The Whole Story For SonoScape Medical (SZSE:300633)

Sep 04

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Aug 18

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Jul 17

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Feb 28

Earnings and Revenue Growth Forecasts

SZSE:300633 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	3,077	N/A	N/A	N/A	1
12/31/2026	3,335	770	465	602	8
12/31/2025	2,776	577	304	714	8
12/31/2024	2,147	238	81	323	5
9/30/2024	2,051	243	56	280	N/A
6/30/2024	2,090	352	151	354	N/A
3/31/2024	2,127	416	227	413	N/A
12/31/2023	2,120	454	312	489	N/A
9/30/2023	1,979	445	260	478	N/A
6/30/2023	1,970	468	273	474	N/A
3/31/2023	1,865	457	282	470	N/A
1/1/2023	1,763	370	283	473	N/A
9/30/2022	1,756	353	261	460	N/A
6/30/2022	1,637	313	177	375	N/A
3/31/2022	1,533	262	167	356	N/A
1/1/2022	1,445	247	151	303	N/A
9/30/2021	1,391	66	220	322	N/A
6/30/2021	1,320	38	287	374	N/A
3/31/2021	1,211	-2	208	348	N/A
12/31/2020	1,163	-46	116	271	N/A
9/30/2020	1,176	65	45	193	N/A
6/30/2020	1,195	54	-30	141	N/A
3/31/2020	1,258	81	15	153	N/A
12/31/2019	1,254	102	32	190	N/A
9/30/2019	1,224	146	63	212	N/A
6/30/2019	1,231	207	90	220	N/A
3/31/2019	1,226	244	115	230	N/A
12/31/2018	1,227	253	153	234	N/A
9/30/2018	1,144	246	-1	92	N/A
6/30/2018	1,106	234	N/A	129	N/A
3/31/2018	1,060	201	N/A	99	N/A
12/31/2017	989	190	N/A	139	N/A
9/30/2017	963	192	N/A	175	N/A
6/30/2017	885	171	N/A	146	N/A
3/31/2017	784	134	N/A	157	N/A
12/31/2016	719	130	N/A	137	N/A
3/31/2016	650	103	N/A	94	N/A
12/31/2015	686	106	N/A	56	N/A
12/31/2014	640	132	N/A	114	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300633's forecast earnings growth (54% per year) is above the savings rate (2.8%).

Earnings vs Market: 300633's earnings (54% per year) are forecast to grow faster than the CN market (25.2% per year).

High Growth Earnings: 300633's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300633's revenue (13.5% per year) is forecast to grow slower than the CN market (13.5% per year).

High Growth Revenue: 300633's revenue (13.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300633's Return on Equity is forecast to be low in 3 years time (15.4%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 05:39
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SonoScape Medical Corp. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zhishun Siu	CCB International Securities Limited
Pei Cheng	China Galaxy Securities Co., Ltd.
Xipeng Feng	China International Capital Corporation Limited

SonoScape Medical Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Price target decreased by 7.8% to CN¥50.15

Price target decreased by 8.0% to CN¥57.34

Price target decreased by 7.4% to CN¥62.43

Price target increased to CN¥71.16

Price target increased to CN¥30.86

Recent updates

Is SonoScape Medical (SZSE:300633) Using Too Much Debt?

SonoScape Medical Corp. to Report Fiscal Year 2024 Results on Apr 12, 2025

Is There An Opportunity With SonoScape Medical Corp.'s (SZSE:300633) 23% Undervaluation?

Now 21% undervalued

Now 22% overvalued after recent price rise

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 23% overvalued

Investors Appear Satisfied With SonoScape Medical Corp.'s (SZSE:300633) Prospects As Shares Rocket 28%

Investor sentiment deteriorates as stock falls 19%

SonoScape Medical Corp. to Report Q3, 2024 Results on Oct 26, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

These 4 Measures Indicate That SonoScape Medical (SZSE:300633) Is Using Debt Reasonably Well

Weak Statutory Earnings May Not Tell The Whole Story For SonoScape Medical (SZSE:300633)

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

SonoScape Medical Corp. to Report First Half, 2024 Results on Aug 29, 2024

Does SonoScape Medical (SZSE:300633) Have A Healthy Balance Sheet?

Dividend increased to CN¥0.32

SonoScape Medical Corp. 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024

Pinning Down SonoScape Medical Corp.'s (SZSE:300633) P/E Is Difficult Right Now

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 7.8% to CN¥50.15

Full year 2023 earnings: EPS misses analyst expectations

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp. to Report Q1, 2024 Results on Apr 27, 2024

We Think SonoScape Medical (SZSE:300633) Can Manage Its Debt With Ease

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Less than half of directors are independent

Investor sentiment improves as stock rises 17%

SonoScape Medical Corp. Approves Board Elections

SonoScape Medical Corp. to Report Fiscal Year 2023 Results on Apr 12, 2024

Price target decreased by 8.0% to CN¥57.34

Now 21% undervalued

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.4% to CN¥62.43

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape Medical Corp. to Report Q2, 2023 Results on Aug 23, 2023

SonoScape Medical Corp. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 08 June 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

Price target increased to CN¥71.16

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.076 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Sonoscape Medical Corp. Announces Final Dividend on Share A for 2021, Payable on July 15, 2022

SonoScape Medical Corp. Approves 2021 Profit Distribution Plan

SonoScape Medical Corp. Proposes Final Cash Dividend for 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape S-Fetus 4.0 Release to Simplify Sonography Process

SonoScape Medical Corp. Receives FDA 510(k) Clearance for HD-550 Endoscopy system

Third quarter 2021 earnings released: EPS CN¥0.076 (vs CN¥0.004 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.085 in 2Q 2020)

SonoScape Obtains CE-Mark for Its Linear Array Echoendoscope EG-UC5T

Price target increased to CN¥30.86

Sonoscape Medical Corp. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.02 loss in 1Q 2020)

New 90-day low: CN¥20.36

SonoScape Medical Corp. Announces Executive Election